I A L S N 

Home

About Us

Our Vision

Our Team

Membership

Sponsorship

Calendar of Events

Newsletters

Photo Gallery

Presentations

Jobs & Candidates

Forms

Contact US

Iranian American Life Science Network
Afshin Bahador
Thursday, September 29, 2011
 

"The Application of Robotics Technology in the Field of Surgery"

Dr. Afshin Bahador 

The application of robotics technology in the field of surgery has become one of the most significant human achievements in the early 21st century.  The technology is rapidly replacing the more traditional surgical approaches and is fast becoming the “standard of care”.  Dr. Bahador will discuss the evolution of robotic surgery in the past two decades, and will place special emphasis on its impact in the field of gynecologic oncology.


Dr. Afshin Bahador is a board certified gynecologic oncologist who is currently practicing in San Diego, CA.  He is a graduate of University of Southern California, Keck School of Medicine. He completed his residency in obstetrics and gynecology, followed by subspecialty training in gynecologic oncology at USC/Los Angeles County Medical Center.  He provides comprehensive gynecologic cancer care.  Dr. Bahador is recognized both locally and nationally as a leader in robotic surgery in gynecology.   He has been honored with numerous awards including San Diego’s Top Doctor in the past 6 consecutive years.
Dr. Parick O'Connor
Dr. Partrick O'Connor

Thursday, June 23, 2011

 
"From Bedside to Bench to Bedside Again: Personalizing Cancer
Care Using Primary Tumor Model Systems"  

Dr. Patrick O'Connor
Founder & CSO, Selexagen Therapeutics, Inc.
Former Vice President, Head of Oncology Research at
Pfizer, Inc.   
Dr. O'Connor is a leader in the field of oncology drug discovery and development. His contributions include over 100 publications and patents, and over 20 compounds brought into development (e.g., Axitinib (VEGF, PII/PIII), AG14699/PF-01367338 (PARP, PII/III), Crizotinib (C-Met/ALK, PII/III)), RDEA119/BAY869766 (MEK, Phase I/II). Prior to joining the industry, Dr. O'Connor spent 10 years at the National Cancer Institute in Bethesda, Maryland. He then joined Agouron Pharmaceuticals which was later acquired by Pfizer, Inc. at which he became the Head of Oncology Research. Dr. O'Connor has also contributed research or scientific advisory board duties at Ardea Biosciences, Halozyme Therapeutics and Ruga Corporation. Dr. O’Connor is currently a Senior Editor of the journal Cancer Research, and Founder & Chief Scientific Officer of Selexagen Therapeutics, Inc.


The event includes buffet dinner, desert and soft drinks/wine. Because there are a limited number of spaces available, it is advisable to register soon.
Mark Benedyk
Mark Benedyk
Thursday, January 27, 2011 

"Life Sciences Financing in 2011: Trends for the New Year "
Dr. Mark Benedyk 

2010 was a game-changing year for private investment in biotech and companies are on the lookout for new sources of financing as traditional capital providers pull away from the sector.  This talk is an overview of life science investment trends for 2011 and outlines changes in the market for biotech capital, highlighting emerging capital providers that are increasingly important for startups as traditional capital providers continue to contract.

Mark Benedyk is Managing Partner of Rila Partners LLC, a life sciences strategy and business development advisory firm based in San Diego.  Prior to founding Rila, Dr. Benedyk was managed The Pfizer Incubator LLC, an option fund created by Pfizer to offer scientist-entrepreneurs opportunities to bring their medical innovations to patients. Prior to joining The Pfizer Incubator, Dr. Benedyk was Vice President of Business Development at Ascenta Therapeutics, a clinical-stage oncology company. There he managed the patent estate for the company, led all contract and licensing negotiations for Ascenta, and was part of the executive team that secured $50 million for Ascenta's Series C financing.

Before coming to Ascenta, Dr. Benedyk was Vice President of Business Development and Director of Optimer Biotechnology, an international subsidiary of Optimer Pharmaceuticals, with operations in the U.S. , Singapore and Taiwan . While there, he managed the patent estate for the company, led business development activities for Optimer Biotechnology in Singapore, and was part of the executive team that raised $22 million for the Series C&D financing rounds for Optimer prior to its successful IPO in February of 2007.

Previously, Dr. Benedyk held business development positions at rila bioconsulting, Farmal Biomedicines, Aurora Biosciences (now Vertex Pharmaceuticals), Élan Pharmaceuticals, and Argonex Corporation. During his tenure in the pharmaceutical and biotechnology industries, Dr. Benedyk has personally led transactions worth over $300 million and participated in over $600 million worth of product licensing, corporate acquisition and fundraising transactions. Dr. Benedyk received his Ph.D. in Genetics and Developmental Biology from The Rockefeller University, where he was a Lucille P. Markey Graduate Fellow. He received his B.S. in Microbiology and Botany from the University of Michigan .


 
Mo Tehrani
Mo Tehrani

December 2010

  "RNAi, An Opportunity For a New Class of Drugs?"
Mo Tehrani
RNAi Discovery and Therapeutics Services
 
Presentation will cover this breakthrough molecular biology technology from its discovery just 10 years ago to the current RNAi potential and candidates in clinical trials.
 
Mo Tehrani is a graduate UCSD with a Bachelors of Science in Biochemistry and Cell Biology. He worked as a scientist at The Scripps Research Institute investigating G-protein cell signaling pathways associated with integrins. He transitioned into industry after four years behind the bench and is now with Thermo Fisher Scientific, the leading provider of RNAi tools for research and discovery. Mo Tehrani manages the RNAi Discovery and Therapeutic Services business globally for Thermo.
The Power of Outsourcing in Early through Preclinical Drug Development
September, 9th 2010

Hyatt Regency in La Jolla

Mark your calendar and plan to join us for a one day Symposium featuring 9 senior level pharmaceutical and biotechnology industry speakers in a keynote address, case study presentations and discussions covering hot topics and end-to-end solutions across the drug-development spectrum.
The presentations will explore a number of issues related to “Early through Preclinical Drug Development” and features internationally recognized experts in drug discovery and development discussing topics including:

Keynote Topic:
The objective of this presentation is to provide the biotech companies the most effective ways of outsourcing pre-clinical testing. These will include identifying the criteria for choosing the appropriate contract lab based on its history, capabilities, expertise, and finally making a choice between science and quality of the product versus cost.
The Power of Outsourcing in Early through Preclinical Drug Development _ September, 9th 2010_San Diego

Ali Faqi, Ph.D., DVM, DABT, MPI
The Power of Outsourcing in Early through Preclinical Drug Development _ September, 9th 2010_San Diego
Pfizer The Power of Outsourcing in Early through Preclinical Drug Development _ September, 9th 2010_San Diego

Grace M. Furman, Ph.D., DABT
CEO/President, Paracelsus, Inc.
Sylvie K. Sakata, PhD Senior Director
Pfizer Inc. La Jolla and St Louis
Lead External Research Solutions RCoE

The Power of Outsourcing in Early through Preclinical Drug Development _ September, 9th 2010_San Diego
The Power of Outsourcing in Early through Preclinical Drug Development _ September, 9th 2010_San Diego
The Power of Outsourcing in Early through Preclinical Drug Development _ September, 9th 2010_San Diego

David C. Zimmermann, CEO - Kalexsyn Inc.
James McKim, Ph.D., DABT - CSO, CeeTox Inc
John Ryals, Ph.D. - CEO, Metabolon
The Power of Outsourcing in Early through Preclinical Drug Development _ September, 9th 2010_San Diego
The Power of Outsourcing in Early through Preclinical Drug Development _ September, 9th 2010_San Diego





Dean Knuth - CEO, Jasper Clinic 
David McGee, Ph.D., DABT – MPI Research
David Barnes, PhD - CSO, Velesco Pharmaceutical

  
 
Dr. Kourosh Parivar
Dr. Kourosh Parivar

IALSN is proud to present

 
 "Clinical Trials: Phase II"

Guest Speaker
Dr. Kourosh Parivar, M.Pharm.
Vice President
Head, Clinical Pharmacology
Oncology Business Unit

Pfizer Inc.

 

In this talk Phase II studies specifically Proof of Concept (POC) studies will be described and put in relationship to the overall context of Drug Development. Different design alternatives will be explained and topics such as fixed design versus adaptive design will be explained.

 

May 27, 2010

Dr. William Gerwick

Dr. Gerwick talked about “Prospecting for Pharmaceuticals on Coral Reefs: Interesting Science and Educational Opportunities with Societal Applications”. Dr. Gerwik is the professor of Oceanography and Pharmaceutical Sciences Center for Marine Biotechnology and Biomedicine at Scripps Institution of Oceanography, University of California at San Diego. He received his B.S. degree in Biochemistry at the University of California, Davis. His undergraduate Research was in Phycology. He received his Ph.D. from University of California, San Diego Scripps Institution of Oceanography, and was a Postdoctoral Research Associate at the University of Connecticut, School of Pharmacy. 
 
February, 4 2010
Dr. James McKim
Dr. James McKim

IALSN is proud to present

 
"Organotypic In Vitro Models for Accessing the Safety of Pharmaceutical Candidates: An Ala Carte Approach to Screening"  

Dr. Jim McKim
A Diplomat of the American Board of Toxicology
The Founder and Chief Scientific Officer of CeeTox, Inc  

The talk will be focused on a large battery of assays that monitor key biochemical processes and signaling pathways by using new human cell models for liver and kidney that enable teams to monitor normal physiological parameters as well as toxicity pathways.   Three models (liver, kidney, and heart) that focus on target organ specific toxicity will be presented. Assays and cell models that are currently available will be shown as well as new assays in the CeeTox pipeline. In addition, a new real time application called “Study Building” will be demonstrated. This program allows teams to design their own studies based on their immediate needs.  The program provides and allows users to select cell type, assay, exposure concentrations, replicates, and many other variables that determine study scope and cost.  

December 10, 2009
Pardis Sabeti
  
Emancipation, Revolution, and Oppression 

By Dr. Massoum Montakhab

January 29, 2009
 
 Comprehensive Facial Rejuvenation
 by Dr. Amir Karam, MD

September 18, 2008
 
Future Prospects of Dementia  & The New Horizons of Research on the Aging Mind
 by Dr. A. Dean Sherzai
June 10, 2008
 

Patenting and Intellectual Property Rights
 by Dr. Sam Tahmassebi
April 30, 2008
 
From Physics to Pharma: New Tools and Protocols to Maximize Phase I Clinical Trials
by Dr. Ali Arjomand
January 30, 2008


 
 
HIBM
Hereditary Inclusion Body Myopathy 
Daniel K. Darvish, MD
December 12, 2007
This is Dr. Daniel Darvish presentation on HIBM, the rare/orphan disease, therapeutic staratgies, and hope for future. 
Document
HIBM
 
 

History of Medicine in Iran
This is a brief overview  of history of Medicine in Iran. Dr. Mehran Moghadam researched and prepared this beautiful presentation for our March 2007 event.

Document

Copyright  © 2006, IALSN. All Reserved.

Providing a Rich & Focused Network to Life & Medical Science Community